Chris M. Calcaterra served as the Executive Vice President of Global Commercial Operations at Glaukos from April 2022. Before this role, he was the Chief Operating Officer from February 2017 to March 2022 and the Chief Commercial Officer from April 2008 to January 2017. With over 30 years of experience in the ophthalmic medical technology industry, Mr. Calcaterra brings extensive expertise in this area. Prior to joining Glaukos, he was Senior Vice President at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), overseeing the cataract business. Earlier in his career, Mr. Calcaterra held various vice president roles in sales and marketing at Advanced Medical Optics, Inc. and its predecessor surgical division at Allergan, Inc. He holds a B.S. from Miami University and an M.B.A. from Xavier University. Additionally, he was a board member of WaveTec Vision Systems, Inc. (acquired by Novartis).
Gary Berman is the CEO of Tavo Biotherapeutics, leading efforts to develop therapies for severe eye diseases. With over 20 years of experience in healthcare and biotechnology, he has a proven track record in scaling companies and raising over $250 million from top venture capital firms. His notable roles include COO & CFO at Geneo and executive leadership positions at greyspace, Equinox Ophthalmic, and Breathe Technologies. Berman also serves as an advisor to various biotech and medical tech companies, where he leverages his expertise to drive innovation and improve patient care.
Joel Thompson is the VP of Strategy at Tavo Biotherapeutics, overseeing strategic efforts in eye disease therapies. With over 10 years of experience in early-stage startups and management consulting, Joel joined Tavo in April 2024 after his role as an Associate at McKinsey & Company. He holds an MBA from NYU Stern and previously led Fernson Brewing Company through substantial growth and expansion.
